Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Más filtros













Base de datos
Intervalo de año de publicación
1.
J Zoo Wildl Med ; 55(2): 453-461, 2024 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-38875202

RESUMEN

Chytridiomycosis caused by Batrachochytrium dendrobatidis (Bd) has been documented in greater sirens (Siren lacertina) in the wild and in the pet trade. This study evaluated the use of terbinafine-impregnated implants for chytridiomycosis prophylaxis in greater sirens exposed to Bd. Implants were placed intracoelomically in both control (blank implant, n = 4) and treatment (24.5 mg of terbinafine implant, n = 4) groups. Sirens were exposed to Bd zoospores via 24-h immersion bath at 1 and 2 mon postimplant placement. Blood was collected monthly for plasma terbinafine levels, and skin swabs were collected weekly for Bd quantitative PCR. Animals with terbinafine implants had detectable concentrations of plasma terbinafine ranging from 17 to 102 ng/ml. Only one terbinafine-implanted animal had a peak concentration above the published minimum inhibitory concentration for terbinafine against Bd zoospores (63 ng/ml); however, it is unknown how plasma terbinafine concentrations relate to concentrations in the skin. There was no difference between the two treatment groups in clinical signs or Bd clearance rate, and no adverse effects from implants were observed. These findings indicate using intracoelomic drug implants for drug delivery in amphibians is safe; however, terbinafine efficacy in preventing Bd chytridiomycosis in sirens remains unclear. Further investigation of the use of intracoelomic implants and identification of effective drugs and doses in other amphibian species against Bd and other infectious diseases is warranted, as this may provide a practical method for long-term drug delivery in wildlife.


Asunto(s)
Antifúngicos , Terbinafina , Terbinafina/administración & dosificación , Terbinafina/uso terapéutico , Terbinafina/farmacología , Animales , Proyectos Piloto , Antifúngicos/administración & dosificación , Antifúngicos/uso terapéutico , Antifúngicos/farmacocinética , Implantes de Medicamentos , Batrachochytrium/efectos de los fármacos , Masculino , Micosis/veterinaria , Micosis/tratamiento farmacológico , Anfibios
2.
Environ Microbiol Rep ; 16(3): e13274, 2024 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-38775382

RESUMEN

The pathogenic fungus Batrachochytrium dendrobatidis has caused declines of amphibians worldwide. Yet our understanding of how water quality influences fungal pathogenicity is limited. Here, we reviewed experimental studies on the effect of water quality on this pathogen to determine which parameters impacted disease dynamics consistently. The strongest evidence for protective effects is salinity which shows strong antifungal properties in hosts at natural levels. Although many fungicides had detrimental effects on the fungal pathogen in vitro, their impact on the host is variable and they can worsen infection outcomes. However, one fungicide, epoxiconazole, reduced disease effects experimentally and likely in the field. While heavy metals are frequently studied, there is weak evidence that they influence infection outcomes. Nitrogen and phosphorous do not appear to impact pathogen growth or infection in the amphibian host. The effects of other chemicals, like pesticides and disinfectants on infection were mostly unclear with mixed results or lacking an in vivo component. Our study shows that water chemistry does impact disease dynamics, but the effects of specific parameters require more investigation. Improving our understanding of how water chemistry influences disease dynamics will help predict the impact of chytridiomycosis, especially in amphibian populations affected by land use changes.


Asunto(s)
Anfibios , Batrachochytrium , Calidad del Agua , Animales , Batrachochytrium/efectos de los fármacos , Anfibios/microbiología , Micosis/microbiología , Micosis/veterinaria , Micosis/prevención & control , Salinidad , Fungicidas Industriales/farmacología , Quitridiomicetos/efectos de los fármacos , Quitridiomicetos/patogenicidad , Plaguicidas/farmacología , Desinfectantes/farmacología , Antifúngicos/farmacología
3.
PLoS One ; 16(10): e0258185, 2021.
Artículo en Inglés | MEDLINE | ID: mdl-34644335

RESUMEN

Ivermectin is a broad-spectrum antiparasitic medicine, which is often used as a treatment for parasites or as a prophylaxis. While studies have looked at the long-term effects of Ivermectin on helminths, studies have not considered the long-term impacts of this treatment on host health or disease susceptibility. Here, we tracked the effects of early life Ivermectin treatment in Cuban tree frogs (Osteopilus septentrionalis) on growth rates, mortality, metabolically expensive organ size, and susceptibility to Batrachochytrium dendrobatidis (Bd) infection. One year after exposure, there was no effect of Ivermectin exposure on frog mass (X21 = 0.904, p = 0.34), but when tracked through the exponential growth phase (~2.5 years) the Ivermectin exposed individuals had lower growth rates and were ultimately smaller (X21 = 7.78, p = 0.005; X21 = 5.36, p = 0.02, respectively). These results indicate that early life exposure is likely to have unintended impacts on organismal growth and potentially reproductive fitness. Additionally, we exposed frogs to Bd, a pathogenic fungus that has decimated amphibian populations globally, and found early life exposure to Ivermectin decreased disease susceptibility (disease load: X21 = 17.57, p = 0.0002) and prevalence (control: 55%; Ivermectin: 22%) over 2 years after exposure. More research is needed to understand the underlying mechanism behind this phenomenon. Given that Ivermectin exposure altered disease susceptibility, proper controls should be implemented when utilizing this drug as an antiparasitic treatment in research studies.


Asunto(s)
Anuros/crecimiento & desarrollo , Anuros/microbiología , Ivermectina/uso terapéutico , Micosis/tratamiento farmacológico , Micosis/veterinaria , Animales , Batrachochytrium/efectos de los fármacos , Susceptibilidad a Enfermedades , Metamorfosis Biológica/efectos de los fármacos
4.
BMC Vet Res ; 17(1): 57, 2021 Jan 28.
Artículo en Inglés | MEDLINE | ID: mdl-33509166

RESUMEN

BACKGROUND: Infectious disease, particularly the fungal disease chytridiomycosis (caused by Batrachochytrium dendrobatidis), is a primary cause of amphibian declines and extinctions worldwide. The transdermal route, although offering a simple option for drug administration in frogs, is complicated by the lack of knowledge regarding percutaneous absorption kinetics. This study builds on our previous studies in frogs, to formulate and predict the percutaneous absorption of a drug for the treatment of infectious disease in frogs. Chloramphenicol, a drug with reported efficacy in the treatment of infectious disease including Batrachochytrium dendrobatidis, was formulated with 20% v/v propylene glycol and applied to the ventral pelvis of Rhinella marina for up to 6 h. Serum samples were taken during and up to 18 h following exposure, quantified for chloramphenicol content, and pharmacokinetic parameters were estimated using non-compartmental analysis. RESULTS: Serum levels of chloramphenicol reached the minimum inhibitory concentration (MIC; 12.5 µg.mL- 1) for Batrachochytrium dendrobatidis within 90-120 min of exposure commencing, and remained above the MIC for the remaining exposure time. Cmax (17.09 ± 2.81 µg.mL- 1) was reached at 2 h, while elimination was long (t1/2 = 18.68 h). CONCLUSIONS: The model, based on in vitro data and adjusted for formulation components and in vivo data, was effective in predicting chloramphenicol flux to ensure the MIC for Batrachochytrium dendrobatidis was reached, with serum levels being well above the MICs for other common bacterial pathogens in frogs. Chloramphenicol's extended elimination means that a 6-h bath may be adequate to maintain serum levels for up to 24 h. We suggest trialling a reduction of the currently-recommended continuous (23 h/day for 21-35 days) chloramphenicol bathing for chytrid infection with this formulation.


Asunto(s)
Antibacterianos/farmacocinética , Bufo marinus/metabolismo , Cloranfenicol/farmacocinética , Absorción Cutánea , Administración Cutánea , Animales , Antibacterianos/administración & dosificación , Antibacterianos/sangre , Batrachochytrium/efectos de los fármacos , Bufo marinus/microbiología , Cloranfenicol/administración & dosificación , Cloranfenicol/sangre , Pruebas de Sensibilidad Microbiana
5.
PLoS One ; 15(10): e0240480, 2020.
Artículo en Inglés | MEDLINE | ID: mdl-33079945

RESUMEN

Global amphibian populations are being decimated by chytridiomycosis, a deadly skin infection caused by the fungal pathogens Batrachochytrium dendrobatidis (Bd) and B. salamandrivorans (Bsal). Although ongoing efforts are attempting to limit the spread of these infections, targeted treatments are necessary to manage the disease. Currently, no tools for genetic manipulation are available to identify and test specific drug targets in these fungi. To facilitate the development of genetic tools in Bd and Bsal, we have tested five commonly used antibiotics with available resistance genes: Hygromycin, Blasticidin, Puromycin, Zeocin, and Neomycin. We have identified effective concentrations of each for selection in both liquid culture and on solid media. These concentrations are within the range of concentrations used for selecting genetically modified cells from a variety of other eukaryotic species.


Asunto(s)
Anfibios/microbiología , Antifúngicos/farmacología , Batrachochytrium/efectos de los fármacos , Batrachochytrium/crecimiento & desarrollo , Micología/métodos , Animales , Batrachochytrium/genética , Bleomicina/farmacología , Cinamatos/farmacología , Pruebas Diagnósticas de Rutina , Evaluación Preclínica de Medicamentos , Higromicina B/análogos & derivados , Higromicina B/farmacología , Pruebas de Sensibilidad Microbiana , Neomicina/farmacología , Puromicina/farmacología , Pirrolidinonas/farmacología , Selección Genética
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA